

Agenda: February 15, 2001

Psychopharmacological Drugs Advisory Committee

Holiday Inn, Gaithersburg, Maryland

NDA 20-919: Zeldox(ziprasidone mesylate IM, Pfizer)

8:00 Call to Order, Introductions

Carol Tamminga, M.D., Chair, PDAC

Conflict of Interest Statement

Sandra Titus, Ph.D., Executive Secretary, PDAC

8:15 Overview for Today's Discussion

Thomas Laughren, M.D., Team Leader, Psychiatric Drug Products Group

8:30 Pfizer Presentations

Efficacy Issues

Rachel H. Swift, M.D., Executive Director, Pfizer Global Research & Development, CNS

Safety Issues

Edmund P. Harrigan, M.D., Vice President, Pfizer Global Research & Development, CNS

10:00 Break

10:30 Committee Discussion

12:00 Lunch

1:00 Open Public Hearing

2:00 Committee Discussion

4:30 Adjourn